Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™, a First-Generation Cold Technology HA by Symatese
As a result of this product expansion, the company has raised its 2028 revenue outlook by $200 million to $700 million.
- As a result of this product expansion, the company has raised its 2028 revenue outlook by $200 million to $700 million.
- “Today’s announcement represents a material step in achieving our goal of transforming Evolus into a multi-product aesthetics company,” said David Moatazedi, Evolus’ President and Chief Executive Officer.
- “We are excited to expand our portfolio with Evolysse™, a highly competitive filler line that complements our fast-growing aesthetic neurotoxin, Jeuveau®.
- “We are particularly excited to partner with Evolus in bringing our next-generation HA filler product line to the U.S.